Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review ; volume:11 ; number:2 ; year:2018 ; pages:527-533
Case reports in oncology ; 11, Heft 2 (2018), 527-533
- Urheber
-
Egloff, Heidi
Kidwell, Kelley M.
Schott, Anne
- DOI
-
10.1159/000491574
- URN
-
urn:nbn:de:101:1-2018122623190554966338
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Egloff, Heidi
- Kidwell, Kelley M.
- Schott, Anne
Ähnliche Objekte (12)
Pulmonary benign metastasising leiomyoma: a single-institution case series
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Clinical and imaging profiles of pulmonary embolism: a single-institution experience
Pulmonary toxicity of polyalkylene glycols
Ado
Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Jürgens, Ado (Ado Günther Georg) * 4.11.1867
Robust IMPT and follow-up toxicity in skull base chordoma and chondrosarcoma—a single-institution clinical experience
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Ado, Martyrologium —
Kiess, Ado
Pulmonary benign metastasising leiomyoma: a single-institution case series
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Clinical and imaging profiles of pulmonary embolism: a single-institution experience
Pulmonary toxicity of polyalkylene glycols
Ado
Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Jürgens, Ado (Ado Günther Georg) * 4.11.1867
Robust IMPT and follow-up toxicity in skull base chordoma and chondrosarcoma—a single-institution clinical experience
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Ado, Martyrologium —
Kiess, Ado
Pulmonary benign metastasising leiomyoma: a single-institution case series
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Clinical and imaging profiles of pulmonary embolism: a single-institution experience
Pulmonary toxicity of polyalkylene glycols
Ado
Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
Jürgens, Ado (Ado Günther Georg) * 4.11.1867
Robust IMPT and follow-up toxicity in skull base chordoma and chondrosarcoma—a single-institution clinical experience
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Ado, Martyrologium —